Search results - 56 results

Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.

induce systemic and local cellular responses. The clinical protection against a challenge using a LPAIV H9N2 strain of the G1 lineage isolated in Morocco in 2016 was associated with a shorter duration of ...

Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.

sensitive areas could be a complementary measure to the disease control strategies already applied. In this study, the efficacy of a novel DNA vaccine, encoding a H5 gene (A/gyrfalcon/Washington/41088-6/2014 ...

Oncolytic Viruses: An Inventory of Shedding Data from Clinical Trials and Elements for the Environmental Risk Assessment.

Publication Type: Peer reviewed scientific article Authors: Onnockx, Sheela; Aline Baldo; Katia Pauwels Source: Vaccines (Basel), Volume 11, Issue 9 (2023) Keywords: biosafety cancer Clinical trials ...

Regulatory expectations on the use of vaccine reference standards for maintaining product quality.

clinical batches that were shown to be safe and efficacious. In any case, when standards are being qualified, the set of release tests should be accompanied by a set of additional characterization assays. ...

COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022.

Chloé Wyndham-Thomas; Koen Blot; Lucy Catteau Source: Euro Surveill, Volume 28, Issue 26 (2023) Keywords: Belgium COVID-19 COVID-19 Vaccines Hospitalization Humans SARS-CoV-2 Vaccine Efficacy Abstract: ...

Duration of Immunity Induced after Vaccination of Cattle with a Live Attenuated or Inactivated Lumpy Skin Disease Virus Vaccine

In addition to the safety and efficacy aspects, it is important to know the duration for which the vaccines confer protective immunity, as this impacts the design of an efficient control and ...

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial.

SARS-CoV-2 Treatment Outcome Abstract: OBJECTIVES: This study aimed to assess the efficacy and safety of 300 mg camostat mesylate three times daily in a fasted state to treat early phase COVID-19 in an ...

Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol

potential strategies against COVID-19, as well as epidemiological patterns. These analyses will complement evidence from efficacy/safety clinical trials, where vulnerable, more complex/heterogeneous ...

Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol.

effectiveness of treatments, and potential strategies against COVID-19, as well as epidemiological patterns. These analyses will complement evidence from efficacy/safety clinical trials, where vulnerable, more ...

QR code

QR code for this page URL